Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports corporate governance changes effective October 9, 2018, with certain actions taking effect on January 10, 2019. The filing addresses the resignation and appointment of directors and the appointment of a principal accounting officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Resignation: John K. Clarke resigned from the Board, effective January 10, 2019. The resignation was not caused by any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Margaret A. Hamburg was elected to fill the vacancy created by Mr. Clarke's resignation, effective January 10, 2019. She will serve as a Class III director.
- Committee Changes: Upon Mr. Clarke's departure, Colleen F. Reitan will join the Audit Committee. Marsha H. Fanucci remains Chair, and Michael W. Bonney remains a member.
- Officer Appointment: Manmeet S. Soni, currently the Chief Financial Officer, was appointed as the principal accounting officer. Michael P. Mason relinquished this title but will continue as Vice President, Finance.
Compensation and Governance Details
Ms. Hamburg's compensation package includes:
- An annual cash fee of $50,000.
- An initial stock option to purchase 18,000 shares, vesting annually over three years.
- Eligibility for annual stock option awards (currently 9,000 shares) vesting in full on the one-year anniversary of the grant date.
- Reimbursement for reasonable travel and related expenses.
- An indemnification agreement consistent with existing non-employee director agreements.
Investor Verification Checklist
- Verify the effective date of Margaret A. Hamburg's board membership (January 10, 2019).
- Confirm the specific vesting schedule for Ms. Hamburg's initial 18,000 share option grant.
- Review the updated composition of the Audit Committee following the transition.
- Confirm Manmeet S. Soni's dual role as Chief Financial Officer and Principal Accounting Officer.